Effects of cassava wax bath as a new therapeutic approach on patients with plantar fasciitis: a double-blind, randomised clinical trial.

Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE

Original Publication: London : Nature Publishing Group, copyright 2011-

Manihot*/chemistry ; Fasciitis, Plantar*/therapy; Humans ; Female ; Male ; Middle Aged ; Double-Blind Method ; Adult ; Treatment Outcome ; Waxes/therapeutic use ; Pain Measurement ; Range of Motion, Articular ; Baths/methods

The aim of this study was to investigate the efficacy of a new therapeutic approach (cassava wax bath: CWB) compared with usual care (paraffin wax bath: PWB) in patients with plantar fasciitis (PF). Forty patients with PF were recruited into the study (CWB group, n = 20, PWB group, n = 20). Patients in the CWB group received cassava wax bath and patients in the PWB group received usual care (PWB). The primary outcome was pain intensity (PI). The secondary outcomes were the pressure pain threshold (PPT), pain frequency (PFr), foot and ankle ability measure (FAAM), and ankle dorsiflexion range of motion (ADROM). All outcomes were assessed before and after the five-week intervention, one month, and three months after the intervention period. After the intervention, statistically significant improvement was found in all outcomes after the intervention period and during the one month and three months follow-up study in both groups (P < 0.05). For all outcomes, no between-group differences were seen at any post-assessment time-point, except for PFr (P < 0.05). In conclusion, the findings of this study indicate that CWB was significantly superior to PWB in reducing PFr. For the other outcomes, CWB and PWB were both equally effective in reducing PI and increasing PPT, FAAM, and ADROM in patients with PF. Therefore, CWB might be considered as a novel useful therapeutic option for PF patients.Trial registration: Thai Clinical Trials Registry (TCTR) (Identification number: TCTR20220128002), First posted date: 28/01/2022.
(© 2024. The Author(s).)

Arch Phys Med Rehabil. 1988 Apr;69(4):286-91. (PMID: 3281631)
Foot (Edinb). 2022 Dec;53:101951. (PMID: 36463613)
Int J Biometeorol. 2023 Oct;67(10):1679-1688. (PMID: 37526763)
Pak J Med Sci. 2013 Apr;29(2):647-50. (PMID: 24353596)
Turk J Phys Med Rehabil. 2018 Oct 27;65(2):184-190. (PMID: 31453560)
Medicine (Baltimore). 2020 Mar;99(12):e19519. (PMID: 32195954)
Postgrad Med. 2015 Jan;127(1):57-65. (PMID: 25526231)
Foot Ankle Surg. 2023 Apr;29(3):223-227. (PMID: 36737392)
J Med Assoc Thai. 2015 Jun;98(6):561-7. (PMID: 26219160)
Int J Biol Macromol. 2024 Mar;261(Pt 1):129681. (PMID: 38272417)
J Hand Ther. 1998 Apr-Jun;11(2):148-56. (PMID: 9602972)
Actas Dermosifiliogr. 2017 Apr;108(3):261-264. (PMID: 28010873)
Rheumatology (Oxford). 2010 Jul;49(7):1391-8. (PMID: 20403912)
Arch Phys Med Rehabil. 2013 Jan;94(1):149-63. (PMID: 22885279)
Arthritis Care Res. 1993 Sep;6(3):156-66. (PMID: 8130292)
BMJ. 2012 Oct 10;345:e6603. (PMID: 23054045)
Clin Orthop Relat Res. 1974 Mar-Apr;(99):207-45. (PMID: 4133064)
Foot Ankle Surg. 2014 Sep;20(3):160-5. (PMID: 25103701)
J Hand Ther. 2023 Jul-Sep;36(3):706-712. (PMID: 36914488)
J Multidiscip Healthc. 2011;4:155-64. (PMID: 21655342)
Foot Ankle Surg. 2021 Aug;27(6):643-649. (PMID: 32919897)
Arch Phys Med Rehabil. 2013 Apr;94(4):642-9. (PMID: 23187044)
N Engl J Med. 2004 May 20;350(21):2159-66. (PMID: 15152061)
Disabil Rehabil. 2004 Aug 19;26(16):981-7. (PMID: 15371046)
Int J Rehabil Res. 2008 Jun;31(2):165-9. (PMID: 18467932)
BMC Musculoskelet Disord. 2014 Nov 26;15:399. (PMID: 25428566)
Foot Ankle Surg. 2022 Dec;28(8):1356-1365. (PMID: 35817643)
Foot (Edinb). 2022 May;51:101906. (PMID: 35255402)

0 (Waxes)

Date Created: 20240527 Date Completed: 20240527 Latest Revision: 20240718

20240719

PMC11130329

10.1038/s41598-024-62999-9

38802489